Cargando…

Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development

BACKGROUND: Ritlecitinib is an oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family inhibitor undergoing parallel clinical development for alopecia areata, vitiligo, ulcerative colitis, Crohn’s disease, and rheumatoid arthritis. OBJECTIVE: As studies read out simultaneous...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wojciechowski, Jessica, S Purohit, Vivek, Huh, Yeamin, Banfield, Christopher, Nicholas, Timothy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684409/ https://www.ncbi.nlm.nih.gov/pubmed/37917289 http://dx.doi.org/10.1007/s40262-023-01318-3

Ejemplares similares

Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepatic Impairment on Ritlecitinib Pharmacokinetics
por: Purohit, Vivek, et al.
Publicado: (2023)

Ritlecitinib: First Approval
por: Blair, Hannah A.
Publicado: (2023)

Correction to: Ritlecitinib: First Approval
por: Blair, Hannah A.
Publicado: (2023)

Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
por: Ramírez-Marín, Hassiel Aurelio, et al.
Publicado: (2022)

Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
por: Robinson, Michael F., et al.
Publicado: (2020)

Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients
por: Hughes, Jim H., et al.
Publicado: (2022)

Response Letter to the Editor: “Assumption Checking Before Application of the Prespecified QT Linear Mixed Effect Model is Essential”
por: Huh, Yeamin, et al.
Publicado: (2020)

Population PK and PD Analysis of Domagrozumab in Pediatric Patients with Duchenne Muscular Dystrophy
por: Wojciechowski, Jessica, et al.
Publicado: (2022)

Which is the Ideal JAK Inhibitor for Alopecia Areata – Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
por: Sardana, Kabir, et al.
Publicado: (2023)

Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
por: Wojciechowski, Jessica, et al.
Publicado: (2022)

Correction to: Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
por: Wojciechowski, Jessica, et al.
Publicado: (2022)

Population pharmacokinetic‐pharmacodynamic modelling of platelet time‐courses following administration of abrocitinib
por: Wojciechowski, Jessica, et al.
Publicado: (2022)

Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial
por: King, Brett, et al.
Publicado: (2022)

Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
por: Thaçi, Diamant, et al.
Publicado: (2023)

Population Pharmacokinetic/Pharmacodynamic Modeling of the Effect of Abrocitinib on QT Intervals in Healthy Volunteers
por: Wang, Xiaoxing, et al.
Publicado: (2022)

Evaluation of QT Liability for PF‐05251749 in the Presence of Potential Circadian Rhythm Modification
por: Huh, Yeamin, et al.
Publicado: (2019)

Characterizing the relationships between patient‐reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib
por: Winnette, R., et al.
Publicado: (2022)

Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates
por: Li, Chunze, et al.
Publicado: (2020)

Persistent pharmacokinetic challenges to pediatric drug development
por: Sage, Daniel P., et al.
Publicado: (2014)

The pharmacokinetic–pharmacodynamic modelling framework as a tool to predict drug resistance evolution
por: Witzany, Christopher, et al.
Publicado: (2023)

Drug development for the treatment of onchocerciasis: Population pharmacokinetic and adverse events modeling of emodepside
por: Assmus, Frauke, et al.
Publicado: (2022)

Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis
por: Xie, Rujia, et al.
Publicado: (2019)

Comparing the applications of machine learning, PBPK, and population pharmacokinetic models in pharmacokinetic drug–drug interaction prediction
por: Gill, Jaidip, et al.
Publicado: (2022)

Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole
por: Martin, Paul, et al.
Publicado: (2012)

Clinical Validation of the Covariates Pharmacokinetic Model for Propofol in an Adult Population
por: Hawthorne, Christopher, et al.
Publicado: (2022)

Development of a Population Pharmacokinetic Model for Cyclosporine from Therapeutic Drug Monitoring Data
por: Umpiérrez, Martín, et al.
Publicado: (2021)

Population Pharmacokinetic Meta-Analysis to Bridge Ferumoxytol Plasma Pharmacokinetics Across Populations
por: Plock, Nele, et al.
Publicado: (2014)

Evolution and intelligent design in drug development
por: Agafonov, Roman V., et al.
Publicado: (2015)

Physiologically‐Based Pharmacokinetic Model‐Informed Drug Development for Fenebrutinib: Understanding Complex Drug‐Drug Interactions
por: Chen, Yuan, et al.
Publicado: (2020)

Antimalarial mass drug administration in large populations and the evolution of drug resistance
por: Nguyen, Tran Dang, et al.
Publicado: (2023)

Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children
por: Zhou, W, et al.
Publicado: (2016)

Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs
por: Janssen, J. M., et al.
Publicado: (2023)

Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates
por: Kamath, Amrita V., et al.
Publicado: (2014)

Population pharmacokinetic model of ivermectin in mass drug administration against lymphatic filariasis
por: Alshehri, Abdullah, et al.
Publicado: (2023)

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J., et al.
Publicado: (2022)

Model‐informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma
por: Savic, Radojka M., et al.
Publicado: (2022)

Enantiospecific pharmacokinetics and drug–drug interactions of primaquine and blood-stage antimalarial drugs
por: Chairat, Kalayanee, et al.
Publicado: (2018)

Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs
por: Courlet, Perrine, et al.
Publicado: (2021)

Vortioxetine: Clinical Pharmacokinetics and Drug Interactions
por: Chen, Grace, et al.
Publicado: (2017)

Pharmacokinetic drug-drug interaction and their implication in clinical management
por: Palleria, Caterina, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_gpsrgqa5dvg9cman1r3mseus1k